Sumitomo Mitsui Trust Holdings, Inc. Vaxcyte, Inc. Transaction History
Sumitomo Mitsui Trust Holdings, Inc.
- $168 Billion
- Q3 2025
A detailed history of Sumitomo Mitsui Trust Holdings, Inc. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Sumitomo Mitsui Trust Holdings, Inc. holds 8,346 shares of PCVX stock, worth $377,906. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,346Holding current value
$377,906% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding PCVX
# of Institutions
324Shares Held
139MCall Options Held
229KPut Options Held
160K-
Janus Henderson Group PLC London, X014.7MShares$665 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$543 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA12MShares$542 Million8.5% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$450 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6MShares$272 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.69B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...